CNS Open Data
Latest UpdatesOpen DatasetsClinical TrialsResearch GuidesTrend ReportsGlossaryData SourcesAbout

Medical & Academic Disclaimer: CNS Open Data is an academic neuroinformatics platform indexing open research datasets, preprints, and clinical trial pipelines for researchers and data scientists. Content on this site does not constitute medical advice, clinical diagnosis, or treatment recommendations.

CNS Open Data— Open Science Portal for Central Nervous System Research|Research Guides|Trend Reports|Glossary|Ranking|Open Datasets|About|Privacy Policy|Contact
AlzforumOpenNeuroDANDI ArchiveAgora (AMP-AD)
HomeClinical Trial & PipelineGlobal Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
MS Data AllianceMultiple SclerosisClinical Trial & PipelineFAIR Metadata / API
Commercial Use Allowed - MIT License

Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries

June 15, 2026
Simpson-Yap S, De Brouwer E, Kalincik T, MS Data Alliance & MSIF
DOI: 10.1177/13524585211049737

Study Design & Technical Specifications

Sample Size / Cohort

10,000+ MS Patients across 28 Countries

Subject / Study Model

Human Clinical Cohort

Analytical Modalities

Federated Clinical RegistryEpidemiologyDMT Safety

Primary Abstract & Repository Description

Source: MS Data Alliance
International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data.
CNS Open Data Deep Research Brief

Editorial Critique, Methodological Value & Reusability Guide

Structured via CNS Domain Knowledge Engine

1. Scientific Context & Premise

Primary Premise (MS Data Alliance): "International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data." Within Multiple Sclerosis (MS), this work examines MSDA, Multiple Sclerosis, GDSI, Federated Research, OMOP CDM in relation to paramagnetic rim lesions (PRLs), T2/FLAIR lesion volume, oligoclonal bands, EBV titers, and EDSS progression metrics. Authored by Simpson-Yap S, De Brouwer E, Kalincik T.

2. Study Architecture & Findings

Study Architecture: Human Clinical Cohort (10,000+ MS Patients across 28 Countries) utilizing Federated Clinical Registry, Epidemiology, DMT Safety [DOI: 10.1177/13524585211049737]. Key reported conclusion: "International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data."

3. Secondary Analysis & Reusability

Secondary Analysis Applications: (1) Cross-referencing Federated Clinical Registry, Epidemiology, DMT Safety variables (MSDA, Multiple Sclerosis, GDSI, Federated Research, OMOP CDM) against open repositories in Multiple Sclerosis (MS); (2) Benchmarking feature distributions and effect sizes reported in "Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline"; (3) Informing cohort stratification and endpoint selection.

4. Methodological Caveats & Governance

Methodological Note: When integrating these Federated Clinical Registry, Epidemiology, DMT Safety findings, account for cohort-specific inclusion criteria (10,000+ MS Patients across 28 Countries), potential site/instrument batch effects, and repository license terms (MIT License).

Related CNS Open Data Research Playbooks & Methodology Guides
Multiple Sclerosis (MS) Open Data Guide: Federated Real-World Data (OMOP CDM) & MRI Lesion Analysis
10 min read • Open Playbook
Advanced MS Neuroimaging Pipeline: Automated Lesion Segmentation, Paramagnetic Rim Lesions (PRLs) & Spinal Cord Atrophy Quantification
14 min read • Open Playbook

Data Access, Reproducibility & Analysis Starter Guide

FAIR Open Science & Clinical Metadata Verification Protocol

FAIR Metadata / API

Quick Data Access & Structured Export

Open the primary repository directly or download structured metadata (JSON / CSV) in one click.

Open Primary Data (MS Data Alliance)Download Data

This resource is indexed under FAIR (Findable, Accessible, Interoperable, and Reusable) open-science metadata standards, enabling programmatic cross-referencing across Europe PMC, Semantic Scholar, ClinicalTrials.gov, and CNS Open Data.

Programmatic Data Retrieval (Python Starter Code & Recommended SDKs)

Python Quickstart: Query Europe PMC & Semantic Scholar Metadata

# Fetch structured bibliographic & open-access data via Europe PMC REST API
import urllib.request
import urllib.parse
import json

query = "DOI:\"10.1177/13524585211049737\""
url = f"https://www.ebi.ac.uk/europepmc/webservices/rest/search?query={urllib.parse.quote(query)}&format=json&resultType=core"

with urllib.request.urlopen(url, timeout=10) as response:
    payload = json.loads(response.read().decode("utf-8"))
    results = payload.get("resultList", {}).get("result", [])
    if results:
        record = results[0]
        print("Title:", record.get("title"))
        print("Journal / Source:", record.get("journalTitle") or record.get("bookOrReportDetails"))
        print("Cited By Count:", record.get("citedByCount", 0))

Recommended Open-Source Software & SDKs

NiBabelPython SDK

Read and write access to NIfTI, GIFTI, and BIDS neuroimaging file formats in Python.

Scanpy (scverse)Python / AnnData

Scalable Python toolkit for analyzing AnnData (.h5ad) single-cell gene expression matrices.

Standardized 4-Step Workflow & Governance Checklist

Standardized Acquisition & Preprocessing Workflow

1. Programmatic Metadata & Full-Text OA Retrieval

Query Europe PMC or Crossref REST APIs using the persistent DOI/URL to retrieve structured XML full text, supplementary tables, and grant links.

2. Study Design & Cohort Eligibility Screening

Extract sample size, inclusion/exclusion criteria, and primary outcome endpoints for systematic review (PRISMA) inclusion.

3. Data Availability & Supplementary Repository Linkage

Locate accession numbers (GEO, SRA, OpenNeuro, DANDI, Zenodo, Figshare) referenced in the Data Availability section.

4. Citation Graph & Replication Tracking

Monitor supporting and contrasting citations over time to verify whether key findings have been independently replicated.

Reproducibility & Governance Checklist

  • Verify whether the source is a peer-reviewed journal publication or an unrefereed preprint before clinical citation.
  • Check supplementary data licenses (CC-BY / CC0) when extracting figures or summary statistics for meta-analyses.
  • Cross-reference NCT clinical trial identifiers when evaluating therapeutic efficacy or biomarker endpoints.

Tags & Modalities

Federated Clinical RegistryEpidemiologyDMT Safety#MSDA#Multiple Sclerosis#GDSI#Federated Research#OMOP CDM#Clinical Registry

Bibliometrics, Peer-Review Status & Citation Export

Cross-referenced via Semantic Scholar, Europe PMC & bioRxiv

1. Citation Metrics & Context Breakdown

18
Total Citations
0
Influential Citations

Citation Context Breakdown

Supporting: 0
Mentioning: 18
Contrasting: 0

Key Citing Publications

Mentioning2025
SARS‐COV‐2 Pre‐Exposure Prophylaxis With Tixagevimab‐Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era

M. A. Hoechstetter, Eva‐Maria Hollwich, Doris Illner

Mentioning2024
Clinical Course and Outcomes of COVID-19 in Patients with Multiple Sclerosis

Serap Zengin Karahan, C. Boz

Mentioning2024
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study

A. Vergori, G. Matusali, E. Cimini

Mentioning2024
Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies

Mary Hollist, Abraham Hollist, Katherine Au

Mentioning2023
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis

E. Januel, D. Hajage, P. Labauge

2. Peer-Review Validation & Revision History

Verified Publication / Open Dataset Record

Metadata and license integrity verified against primary repository records.

3. Standardized Academic Citation & BibTeX Export

Selected Format (APA)
Simpson-Yap S et al. (2026). Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries. MS Data Alliance. https://doi.org/10.1177/13524585211049737
BibTeX Entry (LaTeX / Reference Managers)
@article{s2026msda,
  title = {Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries},
  author = {Simpson-Yap S and De Brouwer E and Kalincik T and MS Data Alliance & MSIF},
  year = {2026},
  journal = {MS Data Alliance},
  howpublished = {\url{https://github.com/MS-DATA-ALLIANCE/COVID19-GDSI2021}},
  doi = {10.1177/13524585211049737},
  note = {CNS Open Data: multiple_sclerosis}
}

Related Multiple Sclerosis Research & Datasets

Explore All Datasets
Clinical Trial & PipelineMS Data Alliance

MSDA: COVID19 GDSI LocalDashboard - Federated MS Data Toolkit

Official open-source repository and tool for Multiple Sclerosis federated research and data harmonization under MS-DATA-ALLIANCE.

7/31/2022Read Analysis
Peer-Reviewed PaperEurope PMC

Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».

Multiple sclerosis (MS) is a complex, multifactorial neurodegenerative disease with an aetiology that is still partially elusive. Several risk factors are associated with MS development including genetic predisposition and various environmental stressors; however, recently, viral infections have gained significant attention as a crucial environmental trigger. Despite the well-established link between Epstein-Barr virus (EBV) and MS susceptibility, a single-pathogen model fails to clearly characterise the molecular cascades driving the disease, suggesting that the transition from infection to autoimmune response involves more than one viral agent. In this review we examine the speculation that the interactions among different neurotropic viruses could serve a collective causative role in MS, which is under-researched in the literature at present. We summarise contradictory evidence on the role of different viral agents, including the Herpesviridae family (Human Cytomegalovirus, EBV, Herpes Simplex Viruses HSV-1 and HSV-2, and Varicella Zoster Virus), Paramyxoviridae family (Measles Virus and Rubella Virus), Influenza virus, SARS-CoV-2, and Human Endogenous Retroviruses (HERVs). Through interplay within shared molecular pathways, immune modulation, and activation of latent infections, these viruses may collectively influence the inflammatory and demyelinating processes that characterise MS. This review evaluates the etiological role of viral interplay in MS through the cumulative and interactive effects of these pathogens. The available epidemiological, immunological, and experimental data converge on the concept that viral co-exposures act synergistically to shape MS susceptibility in genetically predisposed individuals. Characterising these viral interactions presents a new research direction for the identification of novel biomarkers and the development of preventative strategies through the targeted control of viral networks.

11/1/2026Read Analysis
PreprintmedRxiv (Neurology)

CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis

BackgroundCNM-Au8, a catalytic nanocrystalline gold suspension, is proposed to support neuronal bioenergetics, but its effect on chronic lesion evolution in multiple sclerosis (MS) has not been reported. ObjectivesTo evaluate the effect of CNM-Au8 on chronic lesion tissue expansion (CLTE). Results...

9/25/2026Read Analysis
Database / PortalMS Data Alliance

MSDA Core Dataset (CDS): Standardized Global Real-World Data Harmonization Framework for Multiple Sclerosis

The MSDA Core Dataset (CDS) establishes a 44-variable international harmonization schema mapped to the OMOP Common Data Model, enabling privacy-preserving federated analytics across global Multiple Sclerosis registries.

8/12/2026Read Analysis
Database / PortalMS Data Alliance

MSDA Global Registry & Cohort Metadata Discovery Catalogue (BigMS Network)

A centralized metadata discovery catalogue indexing over 30 national and international MS registries (>120,000 patients), detailing variable availability for EDSS, relapse history, MRI, fluid biomarkers, and DUA governance.

7/24/2026Read Analysis
Peer-Reviewed PaperEurope PMC

Dietary Patterns and Nutritional Factors in Multiple Sclerosis: A Narrative Review

Research article from Europe PMC.

9/17/2026Read Analysis

Active Clinical Trials & Pipeline in Multiple Sclerosis

View Clinical Pipeline
MSBASE-GLOBAMultiple Sclerosis

MSBase & BigMS Harmonized Cohort: Quantifying Progression Independent of Relapse Activity (PIRA) Under High-Efficacy DMTs

MS Data Alliance
MSDA-COVID19MSDA

Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries

MS Data Alliance
MSDA-GH-GDSIMultiple Sclerosis

MSDA: GDSI Mock DataGenerator - GDSI Mock data generator

MS Data Alliance

Related Data & Resources

Open Datasets

Explore Related Datasets

Find neuroimaging or multi-omics datasets relevant to this topic.

Clinical Trials

View Clinical Pipeline

Check investigational drugs, clinical trials, and clinical guidelines.

Academic Research & Medical Information Disclaimer

This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.

Was this resource helpful?

Help improve data curation by sharing your feedback.

Open SourceDownload Data